Hydrogel of Ketoconazole and PAMAM dendrimers: Formulation and antifungal activity

Molecules

Volumn 17, Issue 4, 2012, Pages 4612-4624

  Winnicka, Katarzyna ^a   Wroblewska, Magdalena ^a   Wieczorek, Piotr ^a   Sacha, Pawel Tomasz ^a   Tryniszewska, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Antifungal activity; Aqueous solubility; Hydrogel; Ketoconazole; PAMAM dendrimer

Indexed keywords

ANTIFUNGAL AGENT; DENDRIMER; KETOCONAZOLE; PAMAM STARBURST;

ARTICLE; CHEMISTRY; HYDROGEL; MICROBIOLOGICAL EXAMINATION; SOLUBILITY;

ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DENDRIMERS; HYDROGEL; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; SOLUBILITY;

EID: 84860250754     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17044612     Document Type: Article

References (37)

1. European Pharmacopoeia, 6th ed.; Council of Europe: Strasbourg, France, 2007; Volume 2, pp. 2216-2217.
2. Borgers, M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev. Infect. Dis. 1980, 2, 520-524.
3. Kauffman, C.A.; Carver, P.L. Use of azoles for systemic antifungal therapy. Adv. Pharmacol. 1997, 39, 143-189.
4. Marriot, M.S. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J. Gen. Microbiol. 1980, 117, 253-255.
5. Gil, C.; Perez-Diaz, R.; Nombela, C. Inhibitory and morphological effects of several antifungal agents on three types of Candida albicans morphological mutants. J. Med. Vet. Mycol. 1994, 32, 151-162.
6. Najlah, M.; D'Emanuele, A. Crossing cellular barriers using dendrimer nanotechnologies. Curr. Opin. Pharmacol. 2006, 6, 522-527.
7. Svenson, S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 2009, 71, 445-462.
8. Tomalia, D.A. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Aldrichimica Acta 2004, 37, 39-57.
9. Tomalia, D.A. Dendrimer research. Science 1991, 252, 1231-1237.
10. Patri, A.K.; Majoros, I.J.; Baker, J.R., Jr. Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 2002, 6, 466-471.
11. Cheng, Y.; Xu, Z.; Ma, M.; Xu, T. Dendrimers as drug carriers: Applications in different routes of drug administration. J. Pharm. Sci. 2008, 97, 123-143.
12. Tulu, M.; Aghatabay, N.M.; Senel, M.; Dizman, C.; Parali, T.; Dulger, B. Synthesis, characterization and antimicrobial activity of water soluble dendritic macromolecules. Eur. J. Med. Chem. 2009, 44, 1093-1099.
13. Polcyn, P.; Jurczak, M.; Rajnisz, A.; Solecka, J.; Urbańczyk- Lipkowska, Z. Design of antimicrobially active small amphiphilic peptide dendrimers. Molecules 2009, 14, 3881-3905.
14. Janiszewska, J.; Sowińska, M.; Rajnisz, A.; Solecka, J.; Ła̧cka, I.; Milewski, S.; Urbańczyk-Lipkowska, Z. Novel dendrimeric lipopeptides with antifungal activity. Bioorg. Med. Chem. Lett. 2012, 22, 1388-1393.
15. Winnicka, K.; Sosnowska, K.; Wieczorek, P.; Sacha, P.T.; Tryniszewska E. Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole. Biol. Pharm. Bull. 2011, 34, 1129-1133.
16. Cheng, Y.; Qu, H.; Ma, M.; Xu, Z.; Xu, P.; Fang, Y.; Xu, T. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. Eur. J. Med. Chem. 2007, 42, 1032-1038.
17. Lebreton, S.; Newcombe, N.; Bradley, M. Antibacterial single-bead screening. Tetrahedron 2003, 59, 10213-10222.
18. Balogh, L.; Swanson, D.R.; Tomalia, D.A.; Hagnauer, G.L.; McManus, A.T. Dendrimer-silver complexes and nanocomposites as antimicrobial agents. Nano Lett. 2001, 1, 18-21.
19. Prajapati, R.N.; Tekade, R.K.; Gupta, U.; Gajbhiye, V.; Jain, N.K. Dendrimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol. Pharm. 2009, 6, 940-950.
20. Kovacs, K.; Stampf, G.; Klebovich, I.; Antal, I.; Ludanyi, K. Aqueous solvent system for the solubilization of azole compounds. Eur. J. Pharm. Sci. 2009, 36, 352-358.
21. Smelcerovic, A.; Knezevic-Jugovic, Z.; Petronijevic, Z. Microbial polysaccharides and their derivatives as current and prospective pharmaceuticals. Curr. Pharm. Des. 2008, 14, 3168-3195.
22. Lopez, A.I.; Reins, R.Y.; McDermott, A.M.; Trautner, B.W.; Cai, C. Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. Mol. Biosyst. 2009, 5, 1148-1156.
23. Venuganti, V.V.K.; Perumal, O.P. Poly(amidoamine) dendrimers as skin penetration enhancers: Influence of charge, generation and concentration. J. Pharm. Sci. 2009, 98, 2345-2356.
24. Alberti, I.; Kalia, Y.N.; Naik, A.; Bonny, J.; Guy, R.H. Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int. J. Pharm. 2001, 219, 11-19.
25. Salerno, C.; Carlucci, A.M.; Bregni, C. Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms. AAPS PharmSciTech. 2010, 11, 986-993.
26. Burnette, R.R.; Ongpipattanakul, B. Characterization of the permselective properties of excised human skin during iontophoresis. J. Pharm. Sci. 1987, 76, 765-773.
27. Gardikis, K.; Hatziantoniou, S.; Viras, K.; Wagner, M.; Demetzos, C. A DSC and Raman spectroscopy study on the effect of PAMAM dendrimer on DPPC model lipid membranes. Int. J. Pharm. 2006, 318, 118-123.
28. Venuganti, V.V.K.; Perumal, O.P. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil. Int. J. Pharm. 2008, 361, 230-238.
29. Cheng, Y.; Man, N.; Xu, T.; Fu, R.; Wang, X.; Wen, L. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J. Pharm. Sci. 2007, 96, 595-602.
30. Akimoto, T.; Aoyagi, T.; Minoshima, J.; Nagase, Y. Polymeric percutaneous drug penetration enhancer. Synthesis and enhancing property of PEG/PDMS block copolymer with cationic end group. J. Control. Release 1997, 49, 229-241.
31. Aoyagi, T.; Terashima, O.; Suzuki, N.; Matsui, K.; Nagase, Y. Polymerization of benzalkonium chloride-type monomer and application to percutaneous drug absorption enhancer. J. Control. Release 1990, 13, 63-71.
32. Tannergren, C.; Knutson, T.; Knutson, L.; Lennernäs, H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 2003, 55, 182-190.
33. De Hoog, G.S.; Guarro, J. Atlas of Clinical Fungi, 1st ed.; Centraalbureau voor Schimmelcultures: Baarn and Delft, The Netherlands, 1995.
34. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast, Approved Standard, CLSI document M27-A3, 3rd ed.; Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, USA, 2008.
35. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. Third Informational Supplement, CLSI document M27-S3; Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, USA, 2008.
36. Canton, E.; Peman, J.; Viudes, A.; Quindos, G.; Gobernado, M.; Espinel-Ingroff, A. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 2003, 45, 203-206.
37. Nesseem, D.I. Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. J. Pharm. Biomed. Anal. 2001, 26, 387-399.